----

|       ̈ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------------------------------------|------------------------------------------------------------------------------------------------|

|      x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------------------------------|--------------------------------------------------------------------------------------|

|       ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------------------------------------|------------------------------------------------------------------------------------------|

|       ̈ | SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------------------------------------|---------------------------------------------------------------------------------------------|

| TEKMIRA PHARMACEUTICALS CORPORATION |
|-------------------------------------|

| British Columbia |
|------------------|

| 100—8900 Glenlyon ParkwayBurnaby, British Columbia, Canada, V5J 5J8 |
|---------------------------------------------------------------------------|

| Mark J. Murray100—8900 Glenlyon ParkwayBurnaby, British Columbia, Canada, V5J 5J8Telephone: +1 604 419 3200Facsimile: +1 604 419 3202 |
|---------------------------------------------------------------------------------------------------------------------------------------------|

----

|                             |   |                                      |
|----------------------------------|--------|-------------------------------------------|
| Title of each Class              |   | Name of each exchange on which registered |
| Common Shares, without par value |   | NASDAQ Capital Market                     |

| N/A |
|-----|

| N/A |
|-----|

| U.S. GAAP  x | International Financial Reporting Standards as issuedby the International Accounting Standards Board   ̈ | Other   ̈ |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------|-------------------------|

----

----

| ITEM 19 | EXHIBITS |
|--------------|----------|

| ExhibitNumber |   | Description                                                                                                                                                                                                                                                                                                                                                     |
|---------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          |   |                                                                                                                                                                                                                                                                                                                                                            |
| 1.1*          |   | Notice of Articles and Articles of the Company (incorporated herein by reference to Exhibit 1.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                                  |
|          |   |                                                                                                                                                                                                                                                                                                                                                            |
| 2.1*          |   | Subscription Agreement, between the Company and Alnylam Pharmaceuticals, Inc., dated March 28, 2008 (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                             |
|          |   |                                                                                                                                                                                                                                                                                                                                                            |
| 2.2*          |   | Subscription Agreement, between the Company and Roche Finance Ltd., dated March 31, 2008 (incorporated herein by reference to Exhibit 2.2 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                        |
|          |   |                                                                                                                                                                                                                                                                                                                                                            |
| 4.1†*   |   | Amendment No. 1 to the Amended and Restated Agreement, between the Company (formerly Inex Pharmaceuticals Corporation) and Hana Biosciences, Inc., effective as of May 27, 2009 (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011). |
|          |   |                                                                                                                                                                                                                                                                                                                                                            |
| 4.2†*   |   | Amended and Restated License Agreement, between Inex Pharmaceuticals Corporation and Hana Biosciences, Inc, dated April 30, 2007 (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                          |

| 4.3†* |   | Sublicense Agreement, between Inex Pharmaceuticals Corporation and Alnylam Pharmaceuticals, Inc., dated January 8, 2007 (incorporated herein by reference to Exhibit 4.3 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                                    |
|-------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 4.4†* |   | Amended and Restated License and Collaboration Agreement, between the Company and Alnylam Pharmaceuticals, Inc., effective as of May 30, 2008 (incorporated herein by reference to Exhibit 4.4 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                              |
|        |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 4.5†* |   | Amended and Restated Cross-License Agreement, between Alnylam Pharmaceuticals, Inc. and Protiva Biotherapeutics Inc., dated May 30, 2008 (incorporated herein by reference to Exhibit 4.5 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                   |
|        |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 4.6†* |   | License Agreement, between Inex Pharmaceuticals and Aradigm Corporation, dated December 8, 2004 (incorporated herein by reference to Exhibit 4.6 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                                                            |
|        |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 4.7†* |   | Settlement Agreement, between Sirna Therapeutics, Inc. and Merck & Co., Inc. and Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc., effective as of October 9, 2007 (incorporated herein by reference to Exhibit 4.7 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012). |

| 4.8†* |   | Development, Manufacturing and Supply Agreement, between the Company and Alnylam Pharmaceuticals, Inc., dated January 2, 2009 (incorporated herein by reference to Exhibit 4.8 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012). |
|-------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ExhibitNumber |   | Description |
|---------------|--------|-------------|

|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
|--------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.9†*  |   | Executive Employment Agreement with Ian Mortimer, dated March 26, 2008 (incorporated herein by reference to Exhibit 4.9 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                 |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.10*        |   | Executive Employment Agreement with Ian MacLachlan, dated May 30, 2008 (incorporated herein by reference to Exhibit 4.10 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.11*        |   | Executive Employment Agreement with Mark Murray, dated May 30, 2008 (incorporated herein by reference to Exhibit 4.11 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                   |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.12*        |   | Executive Employment Agreement with Peter Lutwyche, dated January 1, 2009 (incorporated herein by reference to Exhibit 4.12 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                             |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.13*        |   | Share Option Plan amended through May 12, 2009 (including form stock option agreements) (incorporated herein by reference to Exhibit 4.13 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                               |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.14*        |   | Lease Agreement with Canada Lands Company CLC Limited dated December 15, 1997, as amended (incorporated herein by reference to Exhibit 4.14 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                             |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.15*        |   | Form of Indemnity Agreement (incorporated herein by reference to Exhibit 4.15 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                                                           |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.16*        |   | Award Contract with USASMDC/ARSTRAT effective date July 14, 2010 (incorporated herein by reference to Exhibit 4.16 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                      |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.17†* |   | License Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation executed on July 30, 2001 (incorporated herein by reference to Exhibit 4.17 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                           |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.18†* |   | Amendment Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation dated July 11, 2006 (incorporated herein by reference to Exhibit 4.18 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                               |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.19†* |   | Second Amendment Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation dated January 8, 2007 (incorporated herein by reference to Exhibit 4.19 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                      |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.20†* |   | Consent Agreement of the University of British Columbia to Inex/Alnylam Sublicense Agreement dated January 8, 2007 (incorporated herein by reference to Exhibit 4.20 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                    |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.21†* |   | Amendment No. 2 to the Amended and Restated Agreement, between the Company (formerly Inex Pharmaceuticals Corporation) and Hana Biosciences, Inc., effective as of September 20, 2010 (incorporated herein by reference to Exhibit 4.21 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011). |
|         |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 4.22†* |   | License and Collaboration Agreement between the Company and Halo-Bio RNAi Therapeutics, Inc. as of August 24, 2011 (incorporated herein by reference to Exhibit 4.22 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).                                                                  |

----

| ExhibitNumber |   | Description |
|---------------|--------|-------------|
|          |   |

| 4.23*                |   | Loan Agreement with Silicon Valley Bank dated as of December 21, 2011 (incorporated herein by reference to Exhibit 4.23 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).                  |
|----------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 |   |                                                                                                                                                                                                                                                                      |
| 4.24*                |   | Employment Agreement with Paul Brennan dated August 24, 2010 (incorporated herein by reference to Exhibit 4.24 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).                           |
|                 |   |                                                                                                                                                                                                                                                                      |
| 4.25*                |   | Tekmira 2011 Omnibus Share Compensation Plan approved by shareholders on June 22, 2011 (incorporated herein by reference to Exhibit 4.25 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012). |
|                 |   |                                                                                                                                                                                                                                                                      |
| 4.26††*  |   | Settlement Agreement and General Release, by and among Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics Inc., Alnylam Pharmaceuticals, Inc., and AlCana Technologies, Inc., dated November 12, 2012                                                           |
|                 |   |                                                                                                                                                                                                                                                                      |
| 4.27††*  |   | Cross-License Agreement by and among Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics Inc., dated November 12, 2012                                                                                                         |
|                 |   |                                                                                                                                                                                                                                                                      |
| 4.28††** |   | License Agreement by and among Protiva Biotherapeutics Inc. and Marina Biotech, Inc. dated November 28, 2012                                                                                                                                                              |
|                 |   |                                                                                                                                                                                                                                                                      |
| 4.29*                |   | Employment Agreement with Diane Gardiner dated March 1, 2013                                                                                                                                                                                                              |
|                 |   |                                                                                                                                                                                                                                                                      |
| 8.1*                 |   | List of Subsidiaries (incorporated herein by reference to Exhibit 8.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                      |
|                 |   |                                                                                                                                                                                                                                                                      |
| 12.1*                |   | Certification of Chief Executive Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                   |
|                 |   |                                                                                                                                                                                                                                                                      |
| 12.2*                |   | Certification of Chief Financial Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                   |
|                 |   |                                                                                                                                                                                                                                                                      |
| 13.1*                |   | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                                        |
|                 |   |                                                                                                                                                                                                                                                                      |
| 13.2*                |   | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                                        |
|                 |   |                                                                                                                                                                                                                                                                      |
| 15.1*                |   | Consent of KPMG LLP                                                                                                                                                                                                                                                       |
|                 |   |                                                                                                                                                                                                                                                                      |
| 101*                 |   | Interactive Data Files                                                                                                                                                                                                                                                    |

| * | Previously filed. |
|---|-------------------|

| ** | Filed herewith. |
|----|-----------------|

| † | Confidential treatment granted as to portions of this exhibit. |
|---------|----------------------------------------------------------------|

| †† | Confidential treatment has been requested as to portions of this exhibit. |
|----------------|---------------------------------------------------------------------------|

----

|   | TEKMIRA PHARMACEUTICALS CORPORATION                                                              |
|--------|--------------------------------------------------------------------------------------------------|
|   |                                                                                             |
|   | /s/ Mark J. Murray              |
|   | Mark J. Murray                                                                                   |
|   | President and Chief Executive Officer                                                            |

----